The new oncolytic virus encoding TNFα and hIL-2 submits an IND application to advance the clinical plan for ovarian cancer

Recent popular reports from Yimaike ★Cytiva launches Think Big 2.
0, building a bridge between enterprise and capital for innovative drugsYimai Meng broke the news ★Japan approved Daiichi Sankyo's third-generation oncolytic HSV 1 for the treatment of malignant gliomasYimai Meng broke the news, click on the picture, and register now June 17, 2021 / Yimai Ke News eMedClub News/--Recently, the biotechnology company TILT Biotherapeutics announced that it has submitted an IND for the Phase 1 trial of immunotherapy TILT-123 in ovarian cancer
.

The trial will evaluate the safety and effectiveness of the company’s adenovirus cancer immunotherapy TILT-123 and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with platinum-resistant and refractory ovarian cancer, and It aims to obtain data on the role of TILT-123 in the human body
.

Akseli Hemminki, CEO of TILT Biotherapeutics, a biotechnology entrepreneur and cancer clinician, said: “We are very pleased to be able to advance the immunotherapy project and reach the trial of submitting TILT-123 to apply for an IND
.

At the same time, with Swedbank The cooperation will help us to further explore financing options to accelerate the development of our products in the United States and Europe, and advance our products into phase 2 clinical trials
.

" TILT Biotherapeutics Chairman Jyrki Liljeroos said: "Our team and our Partners are committed to making our TILT ® technology provide better oncolytic viral therapies for cancer patients with unmet needs
.

"For more data, scan the QR code for a complete reading.
Summary Oncolytic viruses are a type of natural or genetically modified viruses that can selectively infect tumor cells, replicate in large quantities and eventually lyse tumor cells, and at the same time, they Release tumor antigens and improve tumor microenvironment
.

Oncolytic virus is one of the powerful tools of tumor immunotherapy.
With the understanding and development of virology and genetic engineering technology, scientists can modify the virus gene
.

Today's oncolytic virus therapy can kill High efficiency, good targeting, low side effects, multiple ways of killing tumors, and low cost are the most promising development directions in the field of tumor immunity
.

Strictly speaking, the oncolytic virus is currently approved by the US FDA for marketing and internationally recognized The product has only one T-vec (Imlygic) of Amgen approved by the FDA in 2015.
It is used for the local treatment of melanoma patients.
It is the first oncolytic virus treatment drug approved by the FDA.
It was launched in Europe and Canada in 2016.
Approved for listing
.

Recently, Japan has also accelerated the approval of Delytact (teserpaturev/G47∆) oncolytic virus product for the treatment of malignant glioma
.

This is the first approved for the treatment of malignant glioma in the world Oncolytic virus products
.

Recommended reading: Japan approved Daiichi Sankyo’s third-generation oncolytic HSV 1 for the treatment of malignant gliomas.
Yimai Meng revealed that the domestic research and development strength in the field of oncolytic viruses cannot be underestimated.
In 2003 and 2005, the CFDA approved the listing of SiBiono’s Jinyousheng and Sanwei Bio’s Encore (H101)
.

At present, the research and development of oncolytic viruses in China is in full swing, and many pharmaceutical companies are actively deploying the research and development of oncolytic viruses.
, I believe that with the continuous deepening of understanding of oncolytic viruses, the continuous improvement of virus modification projects and the continuous research of combination therapies, we look forward to more good news of oncolytic viruses in the future
.

Recommended reading: Oncolytic virus IND application for armored CTLA-4 antibody and GM-CSF was approved by the U.
S.
FDA Yimai Meng revealed that it had raised hundreds of millions of funds in half a year, and the oncolytic virus has entered the fast lane Yimai New Observation Reference Materials: 1.
https://tiltbio.
com/science/tilt-123/2.
https:// is always committed to cutting-edge technology, industry trends, and industry insights in bio-innovative drugs According to original news reports, all-media high-end matrix users reached 160,000+, among which industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institutions accounted for more than 5%
.

In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.